Targeting PI3K signalling in cancer: opportunities, challenges and limitations (Q29617685)

Europe PubMed Central

title

Targeting PI3K signalling in cancer: opportunities, challenges and limitations (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

author name string

Engelman JA

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

August 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

published in

Nature Reviews Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

volume

9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

issue

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

30 April 2017

page(s)

550-62

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

30 April 2017

cites work

1 reference

Class I PI3K in oncogenic cellular transformation.

31 March 2020

1 reference

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

Tenets of PTEN tumor suppression

31 March 2020

1 reference

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

31 March 2020

1 reference

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

31 March 2020

1 reference

Signaling network of the Btk family kinases

31 March 2020

1 reference

Phosphoinositide 3-kinases in cell migration

31 March 2020

1 reference

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

31 March 2020

1 reference

SH2 domains recognize specific phosphopeptide sequences

31 March 2020

1 reference

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

31 March 2020

1 reference

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

Phosphatidylinositol-3-OH kinase as a direct target of Ras

31 March 2020

1 reference

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

31 March 2020

1 reference

Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide

31 March 2020

1 reference

A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction

31 March 2020

1 reference

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

31 March 2020

1 reference

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

31 March 2020

1 reference

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

31 March 2020

1 reference

PTEN: a tumour suppressor that functions as a phospholipid phosphatase

31 March 2020

1 reference

The biology and clinical relevance of the PTEN tumor suppressor pathway

31 March 2020

1 reference

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

31 March 2020

1 reference

Pten dose dictates cancer progression in the prostate

31 March 2020

1 reference

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

31 March 2020

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

31 March 2020

1 reference

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

31 March 2020

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

31 March 2020

1 reference

Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains

31 March 2020

1 reference

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

31 March 2020

1 reference

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

31 March 2020

1 reference

Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

31 March 2020

1 reference

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

31 March 2020

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

31 March 2020

1 reference

Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit

31 March 2020

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

31 March 2020

1 reference

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

31 March 2020

1 reference

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

31 March 2020

1 reference

A novel AKT3 mutation in melanoma tumours and cell lines

31 March 2020

1 reference

Colorectal cancer: mutations in a signalling pathway

31 March 2020

1 reference

A new mutational AKTivation in the PI3K pathway

31 March 2020

1 reference

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

31 March 2020

1 reference

Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase

31 March 2020

1 reference

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

31 March 2020

1 reference

Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration

31 March 2020

1 reference

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

31 March 2020

1 reference

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

31 March 2020

1 reference

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

31 March 2020

1 reference

PTEN-deficient cancers depend on PIK3CB.

31 March 2020

1 reference

Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers

31 March 2020

1 reference

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

31 March 2020

1 reference

Signalling by PI3K isoforms: insights from gene-targeted mice.

31 March 2020

1 reference

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

31 March 2020

1 reference

Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition

31 March 2020

1 reference

Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice

31 March 2020

1 reference

mTOR inhibitors in the treatment of cancer

31 March 2020

1 reference

Temsirolimus, an inhibitor of mammalian target of rapamycin

31 March 2020

1 reference

31 March 2020

mTOR and cancer therapy

1 reference

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

31 March 2020

1 reference

mTOR pathway and mTOR inhibitors as agents for cancer therapy

31 March 2020

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

31 March 2020

1 reference

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

31 March 2020

1 reference

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

31 March 2020

1 reference

Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.

31 March 2020

1 reference

Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.

31 March 2020

1 reference

Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation

31 March 2020

1 reference

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

31 March 2020

1 reference

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

31 March 2020

1 reference

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

31 March 2020

1 reference

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

31 March 2020

1 reference

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

31 March 2020

1 reference

A family with severe insulin resistance and diabetes due to a mutation in AKT2.

31 March 2020

1 reference

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

31 March 2020

1 reference

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

31 March 2020

1 reference

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

31 March 2020

1 reference

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

31 March 2020

1 reference

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

31 March 2020

1 reference

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

31 March 2020

1 reference

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer

31 March 2020

1 reference

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

31 March 2020

1 reference

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

31 March 2020

1 reference

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

31 March 2020

1 reference

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line

31 March 2020

1 reference

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

31 March 2020

1 reference

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

31 March 2020

1 reference

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

31 March 2020

1 reference

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer

31 March 2020

1 reference

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

31 March 2020

1 reference

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

Non-parametric quantification of protein lysate arrays

31 March 2020

1 reference

Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry

31 March 2020

1 reference

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

31 March 2020

1 reference

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

31 March 2020

1 reference

Isolation of rare circulating tumour cells in cancer patients by microchip technology

31 March 2020

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

31 March 2020

1 reference

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

31 March 2020

1 reference

Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ

31 March 2020

1 reference

Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

31 March 2020

1 reference

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

31 March 2020

1 reference

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha

31 March 2020

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 March 2020

1 reference

The phosphoinositide 3-kinase pathway

31 March 2020

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

31 March 2020

1 reference

Oncogenic PI3K deregulates transcription and translation

31 March 2020

1 reference

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

31 March 2020

1 reference

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

31 March 2020

1 reference

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

31 March 2020

1 reference

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

31 March 2020

1 reference

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

31 March 2020

1 reference

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

31 March 2020

1 reference

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

31 March 2020

1 reference

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

31 March 2020

1 reference

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

31 March 2020

1 reference

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

31 March 2020

1 reference

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

31 March 2020

1 reference

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

31 March 2020

1 reference

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

31 March 2020

1 reference

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

31 March 2020

1 reference

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

31 March 2020

1 reference

PIK3CA as an oncogene in cervical cancer

31 March 2020

1 reference

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

31 March 2020

1 reference

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

31 March 2020

1 reference

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

31 March 2020

1 reference

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

31 March 2020

1 reference

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

31 March 2020

1 reference

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

31 March 2020

1 reference

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

31 March 2020

1 reference

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

31 March 2020

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

31 March 2020

1 reference

Perifosine: update on a novel Akt inhibitor.

31 March 2020

1 reference

Pharmacodynamic markers of perifosine efficacy

31 March 2020

1 reference

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

31 March 2020

1 reference

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

31 March 2020

1 reference

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

31 March 2020

1 reference

Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.

31 March 2020

1 reference

12 December 2020

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

1 reference

12 December 2020

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

1 reference

12 December 2020

Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase

1 reference

12 December 2020

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

1 reference

12 December 2020

Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.

1 reference

12 December 2020

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

12 December 2020

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway

1 reference

12 December 2020

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

12 December 2020

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

1 reference

12 December 2020

DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1016821519

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19629070

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017